These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 1804805)

  • 1. Amelioration of thrombocytopenia with concomitant ornithine in sarcoma-bearing rats receiving high dose difluoromethylornithine.
    Grossie VB; Ota DM; Ajani JA; Nishioka K
    Invest New Drugs; 1991 Nov; 9(4):321-6. PubMed ID: 1804805
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reduction of difluoromethylornithine-induced thrombocytopenia in rats with ornithine while maintaining antitumor activity.
    Grossie VB; Ota DM; Ajani JA; Chang TH; Patenia D; Nishioka K
    Cancer Res; 1989 Aug; 49(15):4159-62. PubMed ID: 2501023
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduced tissue ornithine increases the cytotoxicity of difluoromethylornithine.
    Grossie VB; Nishioka K
    Anticancer Res; 1996; 16(6B):3731-5. PubMed ID: 9042249
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of intravenous alpha-difluoromethylornithine on the polyamine levels of normal tissue and a transplantable fibrosarcoma.
    Grossie VB; Ota DM; Ajani JA; Nishioka K
    Cancer Res; 1987 Apr; 47(7):1836-40. PubMed ID: 3102050
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of ornithine in parenteral nutrition regimens on difluoromethylornithine-induced platelet suppression and changes in tumor polyamine content.
    Grossie VB; Nishioka K
    Cancer Invest; 1998; 16(3):160-5. PubMed ID: 9541629
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Red blood cell polyamine levels and host toxicity during continuous alpha-difluoromethylornithine infusion.
    Ota DM; Grossie VB; Ajani JA; Stephens LC; Nishioka K
    Int J Cancer; 1986 Aug; 38(2):245-9. PubMed ID: 3089944
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of difluoromethylornithine on host and tumor polyamine metabolism during total parenteral nutrition.
    Harris WB; Grossie VB; Ota DM; Nishioka K; Ajani JA; Chang T; Patenia D
    J Surg Res; 1985 Jun; 38(6):592-8. PubMed ID: 3925242
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I dose de-escalation trial of alpha-difluoromethylornithine in patients with grade 3 cervical intraepithelial neoplasia.
    Mitchell MF; Tortolero-Luna G; Lee JJ; Hittelman WN; Lotan R; Wharton JT; Hong WK; Nishioka K
    Clin Cancer Res; 1998 Feb; 4(2):303-10. PubMed ID: 9516915
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alterations in polyamine metabolism during continuous intravenous infusion of alpha-difluoromethylornithine showing correlation of thrombocytopenia with alpha-difluoromethylornithine plasma levels.
    Ajani JA; Ota DM; Grossie VB; Levin B; Nishioka K
    Cancer Res; 1989 Oct; 49(20):5761-5. PubMed ID: 2507135
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Antitumor effect of alpha-difluoromethylornithine (DFMO) changes in ornithine decarboxylase (ODC) activity and polyamine (PA) levels in human tumor transplanted into nude mice].
    Umemoto S
    Nihon Geka Gakkai Zasshi; 1989 May; 90(5):650-60. PubMed ID: 2507897
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of deoxyribonucleic acid synthesis by difluoromethylornithine. Role of polyamine metabolism in monocrotaline-induced pulmonary hypertension.
    Hacker AD
    Biochem Pharmacol; 1992 Sep; 44(5):965-71. PubMed ID: 1530663
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined use of alpha-difluoromethylornithine and an inhibitor of S-adenosylmethionine decarboxylase in mice bearing P388 leukemia or Lewis lung carcinoma.
    Nakaike S; Kashiwagi K; Terao K; Iio K; Igarashi K
    Jpn J Cancer Res; 1988 Apr; 79(4):501-8. PubMed ID: 3133338
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemoprevention of colon carcinogenesis by concurrent administration of piroxicam, a nonsteroidal antiinflammatory drug with D,L-alpha-difluoromethylornithine, an ornithine decarboxylase inhibitor, in diet.
    Reddy BS; Nayini J; Tokumo K; Rigotty J; Zang E; Kelloff G
    Cancer Res; 1990 May; 50(9):2562-8. PubMed ID: 2109653
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of the irreversible ornithine decarboxylase inhibitor, alpha-difluoromethylornithine, aflatoxin B1, and choline deficiency on hepatocarcinogenesis.
    Sondergaard D; Taylor F; Newberne PM
    Toxicol Pathol; 1985; 13(1):36-49. PubMed ID: 2412277
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potentiation of the antitumor therapeutic effects of 1,3-bis(2-chloroethyl)-1-nitrosourea by alpha-difluoromethylornithine, an ornithine decarboxylase inhibitor.
    Marton LJ; Levin VA; Hervatin SJ; Koch-Weser J; McCann PP; Sjoerdsma A
    Cancer Res; 1981 Nov; 41(11 Pt 1):4426-31. PubMed ID: 6796258
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I trial and pharmacokinetic study of intravenous and oral alpha-difluoromethylornithine.
    Griffin CA; Slavik M; Chien SC; Hermann J; Thompson G; Blanc O; Luk GD; Baylin SB; Abeloff MD
    Invest New Drugs; 1987; 5(2):177-86. PubMed ID: 3115911
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of continuous-infusion alpha-difluoromethylornithine therapy for colorectal carcinoma.
    Ajani JA; Ota DM; Grossie VB; Abbruzzese JL; Faintuch JS; Patt YZ; Jackson DE; Levin B; Nishioka K
    Cancer Chemother Pharmacol; 1990; 26(3):223-6. PubMed ID: 2113439
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I trial and pharmacokinetic studies of alpha-difluoromethylornithine--an inhibitor of polyamine biosynthesis.
    Abeloff MD; Slavik M; Luk GD; Griffin CA; Hermann J; Blanc O; Sjoerdsma A; Baylin SB
    J Clin Oncol; 1984 Feb; 2(2):124-30. PubMed ID: 6422008
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of tamoxifen and D,L-2-difluoromethylornithine on the growth, ornithine decarboxylase activity and polyamine content of mammary carcinomas induced by 1-methyl-1-nitrosourea.
    Thompson HJ; Ronan AM; Ritacco KA; Meeker LD
    Carcinogenesis; 1986 May; 7(5):837-40. PubMed ID: 3084121
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative antitumor properties in rodents of irreversible inhibitors of L-ornithine decarboxylase, used as such or as prodrugs.
    Claverie N; Mamont PS
    Cancer Res; 1989 Aug; 49(16):4466-71. PubMed ID: 2501026
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.